Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

по Brownstein, Michael J., Simon, Neal G., Long, Jeffrey D., Yankey, Jon, Maibach, Hilda T., Cudkowicz, Merit, Coffey, Christopher, Conwit, Robin A., Lungu, Codrin, Anderson, Karen E., Hersch, Steven M., Ecklund, Dixie J., Damiano, Eve M., Itzkowitz, Debra E., Lu, Shifang, Chase, Marianne K., Shefner, Jeremy M., McGarry, Andrew, Thornell, Brenda, Gladden, Catherine, Costigan, Michele, O’Suilleabhain, Padraig, Marshall, Frederick J., Chesire, Amy M., Deritis, Paul, Adams, Jamie L., Hedera, Peter, Lowen, Kelly, Rosas, H. Diana, Hiller, Amie L., Quinn, Joseph, Keith, Kellie, Duker, Andrew P., Gruenwald, Christina, Molloy, Angela, Jacob, Cara, Factor, Stewart, Sperin, Elaine, Bega, Danny, Brown, Zsazsa R., Seeberger, Lauren C., Sung, Victor W., Benge, Melanie, Kostyk, Sandra K., Daley, Allison M., Perlman, Susan, Suski, Valerie, Conlon, Patricia, Barrett, Matthew J., Lowenhaupt, Stephanie, Quigg, Mark, Perlmutter, Joel S., Wright, Brenton A., Most, Elaine, Schwartz, Guy J., Lamb, Jessica, Chuang, Rosalind S., Singer, Carlos, Marder, Karen, Moran, Joyce A., Singleton, John R., Zorn, Meghan, Wall, Paola V., Dubinsky, Richard M., Gray, Carolyn, Drazinic, Carolyn
Опубликовано в: J Clin Med (2020)